Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	705
Subscription and Copyright Information	616
Advisory Board and Contents	302
Subscription and Copyright Information	291
Subscription and Copyright Information	258
Subscription and Copyright Information	233
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	230
Structural asymmetry in FGF23 signaling	218
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	203
Shearing of surface mucin saps tumor cell strength	196
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	177
Therapeutic inhibition of ferroptosis in neurodegenerative disease	160
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	152
Compstatins: the dawn of clinical C3-targeted complement inhibition	149
Swinging the SWI/SNF complexes for cancer therapy	147
Structural pharmacology and mechanisms of GLP-1R signaling	125
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Cancer pathogenesis and phase targeting through condensate fragility	123
Direct in vivo CAR T cell engineering	121
Advisory Board and Contents	120
Advisory Board and Contents	118
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	115
Advisory Board and Contents	114
A perspective on psychedelic teratogenicity: the utility of zebrafish models	112
Programmable CAR immunotherapies for neurodegenerative proteinopathies	111

Leveraging human microbiomes for disease prediction and treatment	104
Phenotypic approaches for CNS drugs	102
Engineering ACE2 decoy receptors to combat viral escapability	100
Nemolizumab (Nemluvio®) for prurigo nodularis	99
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	97
HSV-1 as a gene delivery platform for cancer gene therapy	96
Genetically engineered loaded extracellular vesicles for drug delivery	89
Ribosome-directed cancer therapies: the tip of the iceberg?	88
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	86
A deep dive into degrader-induced protein-protein interfaces	82
Optogenetic engineering for precision cancer immunotherapy	80
Subscription and Copyright Information	79
Mechanistic insights into nitazenes at the μ-opioid receptor	79
Engineering early immune resilience in islet transplantation	77
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	72
Thriving as members of under-represented groups in pharmacology-related careers	72
Subscription and Copyright Information	70
Emerging approaches to induce immune tolerance to therapeutic proteins	69
Subscription and Copyright Information	67
Now you serine, now you don't	67
Bimetallic nanoadjuvants for cancer vaccines	65
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	65
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	61
Suzetrigine for moderate to severe acute pain	61
Could dexmedetomidine be repurposed as a glymphatic enhancer?	61
Piezo1: structural pharmacology and mechanotransduction mechanisms	60
The structure, function, and pharmacology of MRGPRs	58
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	57
Autologous, allogeneic, in vivo CAR for autoimmune diseases	54
Molecular glues evolve from serendipity to rational design	53
Advancing non-destructive analysis of 3D printed medicines	52
Targeting metabolic vulnerabilities with advanced delivery systems	48
Advisory Board and Contents	46
The road less traveled: activating an oncogenic kinase	45
The promise of targeted protein degradation approaches	44
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities	44
Salt-inducible kinases: new players in pulmonary arterial hypertension?	44
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	44
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	43
Advisory Board and Contents	43
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	42
Promising neuroimmune targets and drugs for CNS diseases	41
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Subscription and Copyright Information	40
The end of the beginning in understanding SLC22 polyspecificity	40
Advisory Board and Contents	40
A novel function of the M2 muscarinic receptor	39
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	39
Monkeypox: potential vaccine development strategies	39
Validation of agent-based models of surface receptor oligomerisation	39

Tackling microbial iron homeostasis: novel antimicrobial strategies	39
PDE4 modulates muscle signaling in cancer cachexia	38
Targeting the assembly of biomolecules: condensate-based drug discovery	37
Chaperones in kinase homeostasis and drug discovery	37
Vepdegestrant for ESR1-mutated breast cancer	35
Protein acylations in cancer immunity: effects and therapeutic opportunities	35
BTK inhibitors: past, present, and future	34
Artificial intelligence in rare diseases: toward clinical impact	34
Frizzleds act as dynamic pharmacological entities	34
Subscription and Copyright Information	33
Advisory Board and Contents	33
Advisory Board and Contents	33
Recent advances in generative biology for biotherapeutic discovery	32
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	32
Topical difamilast for the treatment of mild-to-moderate atopic dermatitis	32
Biosensors for translatable GPCR bias	32
Metabolic regulation in normal and leukemic stem cells	32
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	32
Demographic diversity in platelet function and response to antiplatelet therapy	32
Eflornithine for treatment of high-risk neuroblastoma	31
GPR35 in host–microbe interaction: Mechanisms and translational prospects	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	30
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	30
GPR35: from enigma to therapeutic target	30
Targeting plasma membrane cholesterol as a novel anticancer therapy	29
Development of PROTACs using computational approaches	29
Subscription and Copyright Information	28
Tackling chronic kidney disease in diabetic patients with finerenone	28
Subscription and Copyright Information	28
The structure, function, and pharmacology of SK channel family	27
Biologics and cardiac disease: challenges and opportunities	27
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	27
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	27
Subscription and Copyright Information	27
Targeting sensory neuron GPCRs for peripheral neuropathic pain	27
Boosting CAR-T cell therapy through vaccine synergy	26
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	25
Therapeutic antibodies targeting G protein-coupled receptors	24
Subscription and Copyright Information	24
Recent advancements in vaccine research and development	24
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	24
Neutrophil extracellular traps in wound healing	24
Taming PRMT5–adaptor protein interactions	23
ECM stiffness and epigenetics in organ fibrosis	23
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	22
Subscription and Copyright Information	22
Circadian biology to advance therapeutics for mood disorders	22
The ABCs of psychedelics: a preclinical roadmap for drug discovery	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Chronobiomaterials for circadian-aligned brain therapeutics	21
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	21
Targeting competitive Fe–S regulation to treat Friedreich’s ataxia	21
The structure and function of YTHDF epitranscriptomic m6A readers	20
NLRP3 and pyroptosis blockers for treating inflammatory diseases	20
Challenges and opportunities associated with rare-variant pharmacogenomics	20
August 2026 issue first authors	20
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	20
Subscription and Copyright Information	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Targeting peptide–HLA complexes for precision immunotherapy	19
Advisory Board and Contents	19
Potential for targeting small heat shock protein modifications	19
Glymphatic-stagnated edema induced by traumatic brain injury	18
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
Advisory Board and Contents	18
STING-mediated cancer immunotherapy: emerging modalities and beyond	18
Odorant receptors as potential drug targets	18
β-Arrestins and disease-linked variants: opportunities for targeted modulation	18
Induced proximity for dephosphorylation	18
GPCR-dependent and -independent arrestin signaling	18
Drugging cold-response networks for neuroprotection	18
Subscription and Copyright Information	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	17
Bridging the gap in neuropsychiatric translational research	17
Glaucoma: neuroprotection with NAD-based therapeutic interventions	17
Advisory Board and Contents	17
Celiac disease: mechanisms and emerging therapeutics	16
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	16

Targeting ion channel dysregulation in tumors: emerging therapeutic opportunities	16
Advisory Board and Contents	16
NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	16
Harnessing deep learning for enhanced ligand docking	16
Advancing small-molecule drug discovery by encoded dual-display technologies	16
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	16
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	16
Structural pharmacology of TRPA1 channel	16
Advisory Board and Contents	15
Endometriosis: cannabidiol therapy for symptom relief	15
Mitochondrial dynamics proteins as emerging drug targets	15
Advisory Board and Contents	15
Emerging epigenetic insights into aging mechanisms and interventions	15
Targeting glycosylation to enhance tumor immunotherapy	14
Multiple hERG channel blocking pathways: implications for macromolecules	14
Fluorescent RNAs: new opportunities for drug discovery	14
Isoform-selective targeting of PI3K: time to consider new opportunities?	14
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	14
Current landscape of preclinical models of diabetic cardiomyopathy	14
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	14
Advisory Board and Contents	14
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	14
Advisory Board and Contents	13
Engineering extracellular vesicles for diagnosis and therapy	13
A mechanism for ligand-dependent activation of AHR	13
Halting neuron–fibroblast crosstalk disarms tumor and augments immunotherapy	13
Click chemistry charts covalent drug landscapes in vivo	13
TNIK’s emerging role in cancer, metabolism, and age-related diseases	13
At last: the mitochondrial pyruvate carrier structure revealed!	13
July 2026 issue first authors	12
Present and future of microglial pharmacology	12
Targeting the senescence–autophagy axis for idiopathic pulmonary fibrosis therapy	12
Targeting galectin-3 in inflammatory and fibrotic diseases	12
Recent advances in venom pharmacology reshaping venom-to-drug discovery	12
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation	12
Targeting chromosomal instability and aneuploidy in cancer	12
Engineering cells for solid tumor therapy	12
Nanodelivery of cGAS-STING activators for tumor immunotherapy	11
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	11
Subscription and Copyright Information	11
Heterobifunctional small molecules to modulate RNA function	11
IRAK4: potential therapeutic target for airway disease exacerbations	11
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacology	11
Emerging mechanisms of psilocybin-induced neuroplasticity	11
Targeting developmental reprogramming: hPSC insights for cancer interception	11
Advisory Board and Contents	11
Small molecule modulation of organelle membrane contact sites	11
Advisory Board and Contents	11
Giving ERK a jERK from the endosome	10
February 2026 issue first authors	10
Fezolinetant for menopausal hot flashes and night sweats	10
Targeting the sensory–sympathetic axis for cancer immunotherapy	10
Siglecs in immunotherapy: current clinical landscape and prospects	10
18F-Flurpiridaz PET for imaging of myocardial ischemia	10
Therapeutic targeting of exportin-1 beyond nuclear export	10
Structural snapshot of a β-arrestin-biased receptor	10
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	10
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	10
Neuron–tumor crosstalk fuels small cell lung cancer	10
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	10
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	10
Data-quality-guided AI strategies for natural product drug discovery	9
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	9
Targeting TRPM channels for cerebral ischemia–reperfusion injury	9
Repurposing trifluoperazine for glioblastoma treatment	9
March 2026 issue first authors	9
Subscription and Copyright Information	9
PPAR agonists for the treatment of neuroinflammatory diseases	9
Emerging paradigms and recent progress in targeting ErbB in cancers	9
Subscription and Copyright Information	9
Which HTT transcript to lower?	9
Beyond the blood–brain barrier: the fate of transcytosed therapeutics	9
VMAT structures reveal exciting targets for drug development	9
A quick guide to networking for scientists	9
The structure and function of olfactory receptors	9
Subscription and Copyright Information	8
PSA inhibitors for contraception: insights from prostate cancer	8
Design and development of glucocorticoid receptor modulators	8
Potentiation of GPCR signaling by ATP and sugar monophosphates	8
Data and AI-driven synthetic binding protein discovery	8
Advances in cell therapy: progress and challenges in hematological and solid tumors	8
Gut-derived brain T cells modulate behavior via IFN-γ	8
Some assembly required: a single-RNA vaccine against enterovirus-D68	8
Targeting Fks1 proteins for novel antifungal drug discovery	7
A decoy mutant ACE2 designed to reduce COVID-19	7
Glycine: a long-sought novel ligand for GPR158	7
Orforglipron (Foundayo) for adults with obesity	7
Human carbonic anhydrase modulators: the past, present, and future	7
Mutated G proteins as drug targets	7
Mitochondrial quality control: prime targets for antiviral therapy?	7
Leveraging conformational ensembles in allosteric drug discovery	7
Subscription and Copyright Information	7
Enhancing oncogenic signaling to kill cancer cells	7
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	7
Subscription and Copyright Information	7